Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and impact on survival with treatment
with 90-Y glass microspheres in conjunction with leucovorin, 5-fluorouracil (5-FU) and
oxaliplatin (FOLFOX) as second-line treatment with in patients gemcitabine-refractory
metastatic pancreatic cancer with predominantly liver metastases.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute